vimarsana.com

Page 4 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sartorius Stedim Biotech : First-quarter results of Sartorius Stedim Biotech

Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent A good 23 percentage points of growth contributed by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Stedim Biotech, a leading partner of the biopharma industry, had an exceptionally strong start to fiscal 2021 and grew substantially in order intake 1, sales revenue and earnings. This was fueled by strong fundamental growth, additional business from vaccine manufacturers, and acquisitions.  Many of our products play an essential role in helping to overcome the pandemic. In addition to a very positive general business performance in the first quarter, we accordingly experienced strong demand for our products and technologies used in the production of vaccines and achieved a sharp increase in sales. The substantial rise in the company s profit margin was also supported by underproportionate development of costs, s

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Basilea shareholders approve all proposals of the board of directors at the annual general meeting Basilea Pharmaceutica AGApril 21, 2021 GMT Basel, Switzerland, April 21, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2020. In accordance with the ordinance issued by the Swiss Federal Council (COVID-19 Ordinance 3, extended until December 31, 2021) and the protective measures against the coronavirus that currently apply, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2021 without the physical presence of shareholders. Accordingly, shareholders exercised their voting rights exclusively via the independent proxy. At the AGM, a total of 3,997,434 shareholder votes, equivalent to 30.9 percent of the share capital a

Sartorius with first-quarter uptick in sales and earnings

Sartorius with first-quarter uptick in sales and earnings Read full article Oops! Order intake up 89.2 percent; sales revenue up 61.6 percent; underlying EBITDA margin 33.3 percent 20 percentage points of sales growth influenced by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Logo The life science group Sartorius had an exceptionally strong start in fiscal 2021 and grew substantially in order intake 1, sales revenue and earnings. Businesses related to the coronavirus pandemic additionally fueled this growth. Many of our products play an essential role in helping to overcome the pandemic. In addition to a very positive general business performance in the first quarter, we accordingly experienced strong demand for our products and technologies used in the development and production of vaccines as well as of coronavirus tests and achieved a sharp increase in sales. The substantial rise in the company s p

First-quarter results of Sartorius Stedim Biotech

Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent A good 23 percentage points of growth contributed by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Stedim Biotech, a leading partner of the biopharma industry, had an exceptionally strong start to fiscal 2021 and grew substantially in order intake 1, sales revenue and earnings. This was fueled by strong fundamental growth, additional business from vaccine manufacturers, and acquisitions.  Many of our products play an essential role in helping to overcome the pandemic. In addition to a very positive general business performance in the first quarter, we accordingly experienced strong demand for our products and technologies used in the production of vaccines and achieved a sharp increase in sales. The substantial rise in the company s profit margin was also supported by underproportionate development of costs, s

Investegate |Basilea Pharmaceutica AG Announcements | Basilea Pharmaceutica AG: Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Basilea shareholders approve all proposals of the board of directors at the annual general meeting Basel, Switzerland, April 21, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2020. In accordance with the ordinance issued by the Swiss Federal Council (COVID-19 Ordinance 3, extended until December 31, 2021) and the protective measures against the coronavirus that currently apply, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2021 without the physical presence of shareholders. Accordingly, shareholders exercised their voting rights exclusively via the independent proxy. At the AGM, a total of 3,997,434 shareholder votes, equivalent to 30.9 percent of the share capital and 53.5 percent of the shares entitled to vote, were represented by the independent proxy.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.